Bicara Therapeutics (BCAX) Financials

Balance sheets

30 Sept 202401 June 202401 Dec 202330 Sept 2023

Total Assets

$524.2 M(+151.1%)$208.8 M(-10.8%)$234.0 M-

Current Assets

$521.5 M(+153.1%)$206.1 M(-10.8%)$231.1 M-

Non Current Assets

$2.7 M(-1.8%)$2.7 M(-6.9%)$2.9 M-

Total Liabilities

$14.6 M(-96.2%)$383.6 M(+0.2%)$382.8 M-

Current Liabilities

$14.5 M(-9.9%)$16.1 M(+6.5%)$15.1 M-

Long Term Liabilities

$137.0 K(-100.0%)$367.5 M(-0.1%)$367.7 M-

Shareholders Equity

$509.6 M(+391.6%)-$174.8 M(-17.5%)-$148.8 M-

Book Value

$509.6 M(+391.6%)-$174.8 M(-17.5%)-$148.8 M-

Working Capital

$507.0 M(+166.8%)$190.0 M(-12.0%)$216.0 M-

Cash And Cash Equivalents

$520.8 M(+155.5%)$203.9 M(-11.5%)$230.4 M-

Accounts Payable

$2.0 M(-58.1%)$4.7 M(+47.0%)$3.2 M-

Accounts Receivable

----

Short Term Debt

-$300.0 K(+5.3%)$285.0 K-

Long Term Debt

$137.0 K(-36.9%)$217.0 K(-41.7%)$372.0 K-

Total Debt

$445.0 K(-13.9%)$517.0 K(-21.3%)$657.0 K-

Debt To Equity

0.0(0%)0.0(0%)0.0-

Current Ratio

36.0(+180.7%)12.8(-16.3%)15.3-

Quick Ratio

----

Inventory

----

Retained Earnings

-$200.1 M(-9.6%)-$182.6 M(-19.3%)-$153.0 M-

PB Ratio

2.3---

Income statements

30 Sept 202401 June 202401 Dec 202330 Sept 2023

EPS

-$1.6---$0.7

TTM EPS

-$1.6---$0.7

Revenue

$0.0--$0.0

TTM Revenue

$0.0--$0.0

Total Expenses

$20.6 M--$9.5 M

Operating Expenses

$20.6 M--$9.5 M

Cost Of Goods Sold

----

TTM Cost Of Goods Sold

----

Gross Profit

----

TTM Gross Profit

----

Gross Margin

----

Operating Profit

-$20.6 M---$9.5 M

TTM Operating Profit

-$20.6 M---$9.5 M

Operating Margin

----

Net Income

-$17.5 M---$22.8 M

TTM Net Income

-$17.5 M---$22.8 M

Net Margin

----

EBIT

-$20.6 M---$9.5 M

TTM EBIT

-$20.6 M---$9.5 M

EBITDA

-$20.6 M---$9.5 M

TTM EBITDA

-$20.6 M---$9.5 M

Selling, General & Administrative Expenses

$4.8 M--$2.6 M

TTM SG&A

$4.8 M--$2.6 M

Depreciation And Amortization

$15.0 K--$2000.0

TTM D&A

$15.0 K--$2000.0

Interest Expense

----

TTM Interest Expense

----

Income Tax

$0.0--$0.0

TTM Income Tax

$0.0--$0.0

PE Ratio

----

PS Ratio

----

Cashflow statements

30 Sept 202401 June 202401 Dec 202330 Sept 2023

Cash From Operations

-$17.2 M---$10.5 M

TTM CFO

-$17.2 M---$10.5 M

Cash From Investing

-$8000.0---$150.0 K

TTM CFI

-$8000.0---$150.0 K

Cash From Financing

$334.1 M--$39.9 M

TTM CFF

$334.1 M--$39.9 M

Free Cash Flow

-$17.2 M---$10.7 M

TTM FCF

-$17.2 M---$10.7 M

CAPEX

$8000.0---

TTM CAPEX

$8000.0---

Dividends Paid

----

TTM Dividends Paid

----

TTM Dividend Per Share

----

TTM Dividend Yield

----

Payout Ratio

----